Sciencehealth Policy News

Regulatory Clash as Online Peptide Craze Outpaces Science

The online hype around MOTS-c and other peptides has spawned unregulated use with little human safety data; researchers press for quality-controlled, prescriber-supervised compounding as a safer alternative to the black market, while FDA staff warn against it due to safety gaps; an FDA panel narrowly backed allowing six peptides to be manufactured via compounding—sparking a policy fight over access, safety, and the future of peptide therapies.